Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.

Undiagnosed IgG4 Related Diseases Clinical Trial

Official title:

A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02229448
• Other study ID #: IgG4-RD diagnosis
• Status: Completed
• Phase: N/A
• First received: August 28, 2014
• Last updated: November 15, 2017
• Start date: October 2014
• Est. completion date: September 2015

Study information

• Verified date: August 2014
• Source: Meir Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.

Histopathological analysis of biopsy specimens remains the cornerstone in the diagnosis of IgG4- related disease. Elevated concentrations of IgG4 in tissue and serum are helpful in diagnosing IgG4-related disease, but neither one is a specific diagnostic marker. Correlation with specific histopathological findings is essential, regardless of the serum IgG4 concentration, the number of IgG4-positive plasma cells in tissue, or the ratio of IgG4 to IgG in tissue. Misdiagnoses of IgG4-related disease are increasingly common because of excessive emphasis on moderate elevations of serum IgG4 concentration and overreliance on the finding of IgG4-positive plasma cells in tissue.

Description:

IgG4 is a unique antibody in both structure and function. This molecule accounts for less than 5% of the total IgG in healthy persons and is the least abundant IgG subclass. In contrast to IgG1, IgG2, and IgG3, serum IgG4 concentrations among ostensibly healthy people vary by a factor of more than 100 (normal range, 0.01 to 1.4 mg per milliliter), but IgG4 concentrations within individual persons are generally stable.

Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.

These different conditions were previously thought to be unrelated [2-4]. The commonly shared features include tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic "storiform" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-RD.

Two major presentations of this condition, which often affects more than one organ, are type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and salivary gland disease; the later may present as salivary gland enlargement or as sclerosing sialadenitis (formerly termed "Mikulicz disease" and Küttner's tumor, respectively). These conditions often resemble Sjögren's syndrome but are pathophysiologically distinct from this disorder. The preferred name for the overall condition is IgG4-related disease.

The presence of IgG4-bearing plasma cells is required for a diagnosis of IgG4- related disease, but IgG4-positive cells are found in a wide variety of inflammatory infiltrates, and the detection of substantial numbers of IgG4- positive plasma cells is therefore not diagnostic of IgG4-related disease.

Tissues from patients with IgG4-related disease show diffuse infiltrates of IgG4-bearing plasma cells, in contrast to the focal aggregates of IgG4-bearing cells that are detected in most other inflammatory mimickers of this condition. A diffuse plasma-cell infiltrate with more than 30 IgG4-positive cells per high power field and a ratio of IgG4 to IgG that is higher than 50% provides compelling evidence of IgG4-related disease.

The study will examine the clinical data from the computerized database of Meir Hospital for patient with unknown IGG4-related disease with high serum levels of IGG4 that were admitted for hospitalization for any reason in a period of 14 years, from January 2000 to June 2014.

Since biopsy has proven to be the hallmark in diagnosing IGG4 RD, we decided to complete the investigation in a pool of patients to whom high IGG4 serum levels where confirmed and to whom biopsies from any suitable tissue where obtained for other reasons than IGG4 RD and then to perform specific staining for IGG4 to those samples, by sending them back to the pathology service at our hospital.

Furthermore clinical and other laboratory features of each positive patient will then be correlated from the history of admission of each patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL KFAR SAVA, with at least one result of a high serum level of IGG4 according to the accepted normal range in our laboratory (more than 100mg/dL) and to whom biopsy of a suitable tissue was obtained for other reasons than IGG4 Related Diseases.

• Both genders will be included.

• Patients of all ages.

Exclusion Criteria:

• Patients who have already been diagnosed with IGG4-Related Diseases.

Related Conditions & MeSH terms

• Undiagnosed IgG4 Related Diseases

Locations

Country	Name	City	State
Israel	Meir Medical Center	Kfar-Saba

Sponsors (1)

Lead Sponsor	Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum level of IGG4	Taken from a computerized database	6 months
Secondary	specific staining for IGG4 to biopsy samples	took from biposy that save for clinical trails	six months